Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, which Care Commissioning Groups make provide access to drug Mylotarg.

NHS England, not clinical commissioning groups, is responsible for commissioning most cancer drugs in the National Health Service in England, including gemtuzumab ozogamicin (Mylotarg) for the treatment of untreated acute myeloid leukaemia (AML). NHS England does not currently routinely fund gemtuzumab ozogamicin for the treatment of untreated AML, pending the outcome of the ongoing National Institute for Health and Care Excellence (NICE) technology appraisal. NICE published draft guidance for consultation on the use of gemtuzumab ozogamicin for untreated AML and is currently considering the comments received on its draft recommendations.